nemiralisib (GSK2269557) / GSK 
Welcome,         Profile    Billing    Logout  
 8 Diseases   1 Trial   1 Trial   95 News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nemiralisib (GSK2269557) / GSK
2017-004564-35: A 12 Month Proof of Concept Phase IIa Study of Nemiralisib (GSK2269557) in Symptomatic COPD Participants with a History of Exacerbations

Ongoing
2
400
Europe
Nemiralisib, GSK2269557, Inhalation powder
GlaxoSmithKline Research and Development Ltd., GlaxoSmithKline, S.A., GlaxoSmithKline Research & Development Ltd
Chronic Obstructive Pulmonary Disease (COPD)/chronic bronchitis and emphysema, Chronic Obstructive Pulmonary Disease (COPD)/chronic bronchitis and emphysema, Diseases [C] - Respiratory Tract Diseases [C08]
 
 

Download Options